Screener
Generate Biomedicines, Inc. GENB Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueNoncurrent.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | As of June 30, 2026 | As of December 31, 2025 |
|---|---|---|
| Non-current liabilities: | ||
| Warrant to purchase convertible preferred stock | — | 1,205 |
| Finance lease liabilities, net of current portion | 1,366 | 2,908 |
| Deferred revenue - non-current | — | 4,511 |
| Operating lease liabilities - non-current | 47,643 | 50,610 |
| Other long term liabilities | — | 116 |
| Total liabilities | 105,645 | 141,553 |
| Commitments and contingencies (Note 13) |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s deferred revenue?
- Generate Biomedicines, Inc. (GENB) reported deferred revenue of $0 in Q2 2026.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.
Ask your AI about Generate Biomedicines, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude